Results 21 to 30 of about 19,663 (194)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. [PDF]

PLoS ONE, 2016
OBJECTIVES:To evaluate the performance and treatment profile of advanced EML4-ALK positive Non-small cell lung cancer (NSCLC) patients in a developing country with potentially restricted access to Crizotinib.
Vanita Noronha, Anant Ramaswamy, Vijay M Patil, Amit Joshi, Anuradha Chougule, Subhadha Kane, Rajiv Kumar, Arvind Sahu, Vipul Doshi, Lingaraj Nayak, Abhishek Mahajan, Amit Janu, Kumar Prabhash   +12 more
doaj   +1 more source

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Journal of Translational Medicine, 2019
Background MET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these ...
Wenxian Wang, Hong Wang, Peihua Lu, Zongyang Yu, Chunwei Xu, Wu Zhuang, Zhengbo Song   +6 more
doaj   +1 more source

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer

Thoracic Cancer, 2021
Background Activation of ALK leads to a high level of aerobic glycolysis related to crizotinib insensitivity in anaplastic lymphoma kinase‐positive non‐small cell lung cancer (ALK+ NSCLC).
Caiyu Lin, Hengyi Chen, Rui Han, Li Li, Conghua Lu, Shuai Hao, Yubo Wang, Yong He   +7 more
doaj   +1 more source

Crizotinib Shows Antibacterial Activity against Gram-Positive Bacteria by Reducing ATP Production and Targeting the CTP Synthase PyrG

Microbiology Spectrum, 2022
Infections caused by drug-resistant bacteria are a serious threat to public health worldwide, and the discovery of novel antibacterial compounds is urgently needed.
Yun-Dan Zheng, Tairan Zhong, Haiming Wu, Nan Li, Zuye Fang, Linlin Cao, Xing-Feng Yin, Qing-Yu He, Ruiguang Ge, Xuesong Sun   +9 more
doaj   +1 more source

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.

PLoS ONE, 2017
Anaplastic large cell lymphomas (ALCL) are mainly characterized by harboring the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).
Yuki Uchihara, Fumihito Ueda, Kenji Tago, Yosuke Nakazawa, Tomoyuki Ohe, Tadahiko Mashino, Shigenobu Yokota, Tadashi Kasahara, Hiroomi Tamura, Megumi Funakoshi-Tago   +9 more
doaj   +1 more source

Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature

Case Reports in Hepatology, 2020
Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. Crizotinib-induced hepatotoxicity is a rare event. We report a case of a 46-year-old female with a history of metastatic lung cancer who presented with
Kyle Kreitman, Satheesh P. Nair, Jiten P. Kothadia   +2 more
doaj   +1 more source

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report

Case Reports in Oncology, 2016
Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event.
Jun Osugi, Yuki Owada, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Mitsunori Higuchi, Hiroyuki Suzuki, Mitsukazu Gotoh   +8 more
doaj   +1 more source

Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report

Frontiers in Oncology, 2023
Neoadjuvant targeted therapy is an alternative treatment for locally advanced non-small cell lung cancer (NSCLC) patients with driver gene mutation. MET ex14 mutation is considered a driver gene, and crizotinib is the first oral tyrosine kinase inhibitor
Jiantao Wang, Jiantao Wang, Jiantao Wang, Wenqing Yao, Weiya Wang, Mingyu Fan, Mingyu Fan, Kaili Huang, Kaili Huang, Zhenkun Liu, Zhenkun Liu, Daxing Zhu, Daxing Zhu   +12 more
doaj   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers. [PDF]

Vet Comp Oncol
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Gustafson DL, Early KA, Morales MA, Poplawski KA, Das S, Duval DL.   +5 more
europepmc   +2 more sources

Crizotinib-induced fatal fulminant liver failure [PDF]

, 2016
Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and
van Leerdam, Monique E., Schellens, Jan H M, Huitema, Alwin D R, Schellens, Jan H. M., van Geel, Robin M. J. M., Beijnen, Jos H., Burgers, Sjaak A., Hendrikx, Jeroen J. M. A., Huitema, Alwin D. R., Hendrikx, Jeroen J M A, van den Broek, Daan, Vahl, Jelmer E., Pharmacoepidemiology and Clinical Pharmacology, Sub Clinical Pharmacology, van Geel, Robin M J M   +14 more
core   +1 more source